GPP
EPRX

Great Point Partners’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Great Point Partners’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.93M Hold
1,200,000
– – 1.5% 23
2026
Q1 		$8.69M Hold
1,200,000
– – 2% 20
2025
Q4 		$9.06M Hold
1,200,000
– – 2.94% 13
2025
Q3 		$7.08M Buy
+1,200,000
New +$6.53M 2.92% 14

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Great Point Partners's EPRX Position: Q2 2026 in Review

Great Point Partners held its Eupraxia Pharmaceuticals (EPRX) position steady in Q2 2026 at 1,200,000 shares worth $7.93M. The position accounts for 1.5% of the portfolio, ranked #23.

Great Point Partners first reported a position in EPRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $9.06M in Q4 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Great Point Partners held 1,200,000 shares of Eupraxia Pharmaceuticals worth $7.93M as of Q2 2026.
  • Great Point Partners left its Eupraxia Pharmaceuticals share count unchanged in Q2 2026.
  • Eupraxia Pharmaceuticals made up 1.5% of Great Point Partners's portfolio in Q2 2026, its #23 holding.
  • Great Point Partners first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Great Point Partners's Eupraxia Pharmaceuticals position peaked at $9.06M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.